Evidence mapPaperPMID 39323217Full record

ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2024

Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis.

Kristyna Vochoskova, Sean R McWhinney, Marketa Fialova, Marian Kolenic, Filip Spaniel, Petra Furstova, Petra Boron, Yurai Okaji, Pavel Trancik, Tomas Hajek

Abstract read
In one paragraph

Article in European psychiatry : the journal of the Association of European Psychiatrists, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristyna VochoskovaNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0009-0001-7061-3043
Sean R McWhinneyDepartment of Psychiatry, Dalhousie University, Halifax, NS, Canada.
Marketa FialovaNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0000-0003-3797-2965
Marian KolenicNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0000-0002-2382-3478
Filip SpanielNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0000-0003-3479-696X
Petra FurstovaNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0000-0003-2377-1388
Petra BoronPsychiatric Hospital Bohnice, Prague, Czech Republic.
Yurai OkajiPsychiatric Hospital Bohnice, Prague, Czech Republic.
Pavel TrancikPsychiatric Hospital Bohnice, Prague, Czech Republic.
Tomas HajekNational Institute of Mental Health, Klecany, Czech Republic.ORCID https://orcid.org/0000-0003-0281-8458

Funding

Ministerstvo Zdravotnictví Ceské Republiky NV16-32791A
6 · The paper itself

Abstract

backgroundWe need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.

methodsWe recruited 92 participants with first-episode psychosis (FEP,

resultsMost people started treatment with risperidone (

conclusionsEarly in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

Indexed as

Antipsychotic AgentsBody Mass IndexHospitalizationPsychotic DisordersSchizophreniaWeight GainAdultFemaleHumansMaleOlanzapinePolypharmacyProspective StudiesRisk FactorsRisperidoneYoung AdultAntipsychotic AgentsOlanzapineRisperidoneantipsychoticspolypharmacypredictorschizophreniaweight gain

Identifiers

PMID39323217
PMCPMC11457116

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.